Liminal BioSciences Inc. announced that the Company has nominated a lead preclinical candidate, LMNL6326, for the development of its OXER1 antagonist program, targeting the treatment of eosinophil-driven diseases. The Company is also reported advancement of CTA enabling in vivo studies evaluating LMNL6511, GPR84 antagonist candidate selected for clinical development. Data from these preclinical studies supports progression towards a CTA filing for a Phase 1 first-in-human clinical trial in healthy subjects in the second half of 2023.

Preclinical Study Results for GPR84 Antagonist Development Program. The Company's pipeline is currently made up of three programs. The candidate selected for clinical development, LMNL6511, a selective antagonist for the GPR84 receptor, is expected to commence a Phase 1 clinical trial in the second half of 20 23. The Company is also developing LMNL6326 as an antagonist for the OXER1 receptor, targeting treatment of eosinophIL-driven disease, and GPR40 agonists, both of which are at the preclinical stage.

These statements include those related to Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties. Forward-looking information includes statements concerning, among other things: advancement of Liminal Biosciences' candidates or development programs, including the timing and outcome of the potential development of the Company's R&D programs such as the development of LMNL6511, LMNL6326 and GPR40 agonist discovery program; the timing of initiation or nature of preclinical studies and clinical trials, including the expected filing of a clinical trial authorization or commencement of a Phase 1 clinical trial of LMNL6511 in the second half of 20 2023; the contemplated potential therapeutic areas of product candidates, including IBD, NASH, liver or Eosinophilic mediated diseases; the potential for development programs to address significant unmet medical needs.